Hansa Biopharma (HNSA) KOL event summary

Introduction and agenda

• Event focused on recent Phase 3 trial data and clinical practice insights for imlifidase in highly sensitized kidney transplant patients, featuring presentations, expert discussions, and Q&A sessions with KOLs and company leadership.

• Agenda included topline data presentation, fireside chat, and discussion on challenges for highly sensitized patients.

KOL background and credentials

• Professors Robert Montgomery and Matthew Cooper, leading transplant surgeons and principal investigators for the Confides trial, provided expert insights on clinical impact and unmet needs.

• Panel also included company leadership such as CEO Renée Aguiar-Lucander and CMO Dr. Richard Philipson.

Market insights and analysis

• Approximately 100,000 patients are on the US kidney transplant waiting list, with 10-15% highly sensitized and facing long wait times and increased mortality risk.

• Highly sensitized patients (CPRA >99.9%) have extremely limited access to transplants, with only 0.1 organ offers per year and a 50% five-year waitlist mortality.

• Imlifidase platform targets rapid IgG reduction, enabling transplantation for patients previously considered ineligible.

• IDEFIRIX® is conditionally approved in the EU, with sales of ~SEK 144m YTD 2025 and reimbursement in 21+ countries.